Andrew Chaponnel -- Interim Chief Financial Officer. MESO...

Andrew Chaponnel -- Interim Chief Financial Officer. MESO earnings call for the period ending December 31, 2021.
From transcripts

”We continue our steady investment in manufacturing, including the production of remestemcel-L inventory to support the long-term commercial supply of GVHD, COVID-19 ARDS and IBD. To date, we have manufactured $28 million worth of remestemcel-L inventory in anticipation of launch. This prelaunch inventory will be recognized on the balance sheet if we receive FDA approval”

The US$28m is I believe, referenced here at the lower of cost or net realisable value which may equal hundreds of paediatric doses amounting to 2-3 years supply . If I am correct Ryoncil will achieve reimbursement pricing of approx $600-650k per whole treatment versus hospitalisation costs often treble using standard treatment algorithms. OP

Please do your own research and do not rely on the accuracy of any comments or opinions when making an investment decision.